- Home
- FEBO vs NRSN Comparison
FEBO vs NRSN Comparison
Compare FEBO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- NRSN
- Stock Information
- Founded
- FEBO 1993
- NRSN 2017
- Country
- FEBO Hong Kong
- NRSN Israel
- Employees
- FEBO N/A
- NRSN N/A
- Industry
- FEBO
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- NRSN Health Care
- Exchange
- FEBO Nasdaq
- NRSN Nasdaq
- Market Cap
- FEBO 19.4M
- NRSN 17.8M
- IPO Year
- FEBO 2023
- NRSN 2021
- Fundamental
- Price
- FEBO $1.47
- NRSN $1.09
- Analyst Decision
- FEBO
- NRSN Hold
- Analyst Count
- FEBO 0
- NRSN 1
- Target Price
- FEBO N/A
- NRSN N/A
- AVG Volume (30 Days)
- FEBO 57.8K
- NRSN 294.5K
- Earning Date
- FEBO 10-03-2024
- NRSN 12-18-2024
- Dividend Yield
- FEBO N/A
- NRSN N/A
- EPS Growth
- FEBO N/A
- NRSN N/A
- EPS
- FEBO N/A
- NRSN N/A
- Revenue
- FEBO $16,319,897.00
- NRSN N/A
- Revenue This Year
- FEBO N/A
- NRSN N/A
- Revenue Next Year
- FEBO N/A
- NRSN N/A
- P/E Ratio
- FEBO N/A
- NRSN N/A
- Revenue Growth
- FEBO 9.01
- NRSN N/A
- 52 Week Low
- FEBO $1.20
- NRSN $0.51
- 52 Week High
- FEBO $17.68
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- FEBO 41.24
- NRSN 47.45
- Support Level
- FEBO $1.54
- NRSN $1.01
- Resistance Level
- FEBO $1.72
- NRSN $1.13
- Average True Range (ATR)
- FEBO 0.21
- NRSN 0.09
- MACD
- FEBO -0.00
- NRSN -0.01
- Stochastic Oscillator
- FEBO 8.20
- NRSN 31.03
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.